Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.

We love to hear from our listeners. Send us a message. On this week"s episode of the Business of Biotech, we"re speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company"s thesis, the reasons behind working in stealth mode and when to emerge, and the clinical plan and potential for VIM0423.   Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/